Stay updated on Pralsetinib vs Standard of Care in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.
Latest updates to the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe page shows a new last update date and minor administrative edits; core sections such as eligibility criteria and primary outcomes appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange Detected- Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference3%
- Check33 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%
- Check47 days agoChange DetectedUpdated to Revision: v3.0.2 (replacing v3.0.1); the 'Back to Top' element was removed, a minor UI change.SummaryDifference0.2%
- Check54 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check61 days agoChange DetectedThe web page has been updated to include new information about a clinical study of pralsetinib for advanced non-small cell lung cancer, including details about the study's design, eligibility criteria, and treatment options.SummaryDifference100%
Stay in the know with updates to Pralsetinib vs Standard of Care in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.